Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, Michigan, 48109.
J Cell Biochem. 2013 Nov;114(11):2471-8. doi: 10.1002/jcb.24592.
Erythropoietin (Epo) is used in clinical settings to enhance hematopoietic function and to improve the quality of life for patients undergoing chemotherapy by reducing fatigue and the need for transfusions. However, several meta-analyses have revealed that Epo treatments are associated with an increased risk of mortality in cancer patients. In this study, we examined the role of Epo in prostate cancer (PCa) progression, using in vitro cell culture systems and in vivo bone metastatic assays. We found that Epo did not stimulate the proliferation of PCa cell lines, but did protect PCa cells from apoptosis. In animal models of PCa metastasis, no evidence was found to support the hypothesis that Epo enhances metastasis. Together, these findings suggest that Epo may be useful for treating severe anemia in PCa patients without increasing metastatic risk.
促红细胞生成素（Epo）在临床环境中被用于增强造血功能，并通过减少疲劳和输血需求来提高接受化疗的患者的生活质量。然而，几项荟萃分析表明，Epo 治疗与癌症患者的死亡率增加有关。在这项研究中，我们使用体外细胞培养系统和体内骨转移测定法研究了 Epo 在前列腺癌（PCa）进展中的作用。我们发现，Epo 不会刺激 PCa 细胞系的增殖，但确实可以保护 PCa 细胞免受凋亡。在 PCa 转移的动物模型中，没有证据支持 Epo 增强转移的假设。总之，这些发现表明，Epo 可用于治疗 PCa 患者的严重贫血而不会增加转移风险。
